Possible predictors of response at 1 y after rituximab therapy for ITP
| Variables . | Failure at 1 y (N = 124) . | Response at 1 y (N = 89) . | OR (95% CI) . | P value . |
|---|---|---|---|---|
| Age (y), mean ± SD | 54 ± 20 | 49 ± 20 | 1.012 (0.998-1.026) | .10 |
| Sex (M/F) | 77/47 | 59/30 | 0.833 (0.471-1.473) | .53 |
| ITP duration <1 y before rituximab infusion (n = 87/213) | 44 (36%) | 43 (49%) | 1.715 (0.982-2.994) | .06 |
| Bleeding at ITP diagnosis (n = 90) | 51 (41%) | 39 (44%) | 1.116 (0.644-1.936) | .69 |
| No. of previous treatment lines, median (Q1–3) | 3 (2-4) | 3 (2-4) | 0.944 (0.774-1.151) | .57 |
| Previous splenectomy before rituximab infusion (n = 22) | 15 (12%) | 7 (8%) | 0.62 (0.242-1.591) | .32 |
| Previous transient CR to steroids (n = 46) | 23 (19%) | 23 (26%) | 2 (0.891-4.49) | .09 |
| Previous transient response (R and CR) to IVIG (n = 110) | 65 (71%) | 45 (75%) | 1.2 (0.572-2.516) | .63 |
| Previous transient CR to IVIG (n = 33) | 17 (19%) | 16 (27%) | 1.631 (0.642-4.146) | .30 |
| Platelet count at ITP diagnosis (×109/L), median (Q1-3) | 20 (7-44) | 14 (5-36) | 0.993 (0.981-1.005) | .27 |
| Lower platelet count in the month preceding first rituximab infusion (×109/L), median (Q1-3) | 17 (8-25) | 14 (7-24) | 1.005 (0.992-1.019) | .43 |
| No. of patients with platelet count <10 × 109/L in the month preceding the first rituximab infusion | 31/113* (27%) | 32/82* (39%) | 0.591 (0.322-1.083) | .09 |
| Rituximab infusion regimen | ||||
| 4 infusions | 89 (72%) | 59 (66%) | 0.805 (0.442-1465) | .478 |
| 2 infusions | 34 (28%) | 28 (31%) |
| Variables . | Failure at 1 y (N = 124) . | Response at 1 y (N = 89) . | OR (95% CI) . | P value . |
|---|---|---|---|---|
| Age (y), mean ± SD | 54 ± 20 | 49 ± 20 | 1.012 (0.998-1.026) | .10 |
| Sex (M/F) | 77/47 | 59/30 | 0.833 (0.471-1.473) | .53 |
| ITP duration <1 y before rituximab infusion (n = 87/213) | 44 (36%) | 43 (49%) | 1.715 (0.982-2.994) | .06 |
| Bleeding at ITP diagnosis (n = 90) | 51 (41%) | 39 (44%) | 1.116 (0.644-1.936) | .69 |
| No. of previous treatment lines, median (Q1–3) | 3 (2-4) | 3 (2-4) | 0.944 (0.774-1.151) | .57 |
| Previous splenectomy before rituximab infusion (n = 22) | 15 (12%) | 7 (8%) | 0.62 (0.242-1.591) | .32 |
| Previous transient CR to steroids (n = 46) | 23 (19%) | 23 (26%) | 2 (0.891-4.49) | .09 |
| Previous transient response (R and CR) to IVIG (n = 110) | 65 (71%) | 45 (75%) | 1.2 (0.572-2.516) | .63 |
| Previous transient CR to IVIG (n = 33) | 17 (19%) | 16 (27%) | 1.631 (0.642-4.146) | .30 |
| Platelet count at ITP diagnosis (×109/L), median (Q1-3) | 20 (7-44) | 14 (5-36) | 0.993 (0.981-1.005) | .27 |
| Lower platelet count in the month preceding first rituximab infusion (×109/L), median (Q1-3) | 17 (8-25) | 14 (7-24) | 1.005 (0.992-1.019) | .43 |
| No. of patients with platelet count <10 × 109/L in the month preceding the first rituximab infusion | 31/113* (27%) | 32/82* (39%) | 0.591 (0.322-1.083) | .09 |
| Rituximab infusion regimen | ||||
| 4 infusions | 89 (72%) | 59 (66%) | 0.805 (0.442-1465) | .478 |
| 2 infusions | 34 (28%) | 28 (31%) |
CR, complete response; R, response.
Data are missing for 11 of 124 patients with failure at 1 y and 7 of 89 patients with response at 1 y.